Famotidine, permethrin lotion ANDAs
This article was originally published in The Tan Sheet
Executive Summary
Genpharm receives FDA clearance for famotidine 10 mg tablets (ANDA 75-674) Dec. 21, becoming fourth firm to gain approval for private label stomach remedy equivalent to J&J/Merck's Pepcid AC (1"The Tan Sheet" Aug. 27, 2001, In Brief). Clay-Park Labs' Permethrin Lotion 1% (ANDA 76-090) receives FDA approval Dec. 20 and is second generic version of Pfizer/Warner-Lambert's Nix pediculicide...
You may also be interested in...
Torpharm ANDA
Private labeler's famotidine 10 mg tablets (J&J/Merck's Pepcid AC) approved by FDA March 12. ANDA (75-610) marks fifth private label approval for the H2 antagonist, behind Ivax, Teva (licensed by Perrigo), Dr. Reddy's Labs (licensed by Leiner), Genpharm (1"The Tan Sheet" Jan. 7, 2002, In Brief)...
Leiner
Private labeler to begin shipping generic famotidine 10 mg, marketed under ANDA approval granted to Dr. Reddy's Labs, by Oct. 1. Dr. Reddy's ANDA 75-758 for J&J/Merck Pepcid AC equivalent received FDA clearance Aug. 17; Leiner currently markets generic ranitidine 75 mg (Pfizer/Warner-Lambert's Zantac 75) for Dr. Reddy's. Leiner joins Perrigo (marketing under a license from Teva) and Ivax in OTC generic famotidine market (1"The Tan Sheet" Aug. 6, In Brief)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”